Romidepsin News and Research

RSS

New bacterial enzyme blueprint could accelerate cancer treatment development

A team of researchers at the University of Warwick and Monash University has solved a puzzle that's stumped drug developers for decades: how bacteria naturally create multiple versions of powerful cancer therapies.

1 Jul 2026

Engineered bacteria may improve precision cancer drug delivery

Every year, millions of people are diagnosed with cancer globally; however, current treatments are limited by disease complexity.

17 Mar 2026

Drug combination can bypass cellular defenses in neuroblastoma

A discovery from Australian researchers could lead to better treatment for children with neuroblastoma, a cancer that currently claims 9 out of 10 young patients who experience recurrence.

29 Nov 2025

Drug combination shows promise for treating aggressive T-cell lymphomas

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell transplants, but the disease needs to be brought under control before patients can undergo this treatment.

2 Jul 2025

Danish researchers take an important step in finding a cure for HIV

For around 40 years, scientists all over the world have been unsuccessfully trying to find a cure for HIV, but now a team of researchers from Aarhus University and Aarhus University Hospital have apparently found an important element in the equation.

17 Oct 2022

Epigenetic abnormalities in hematopoietic cells during fetal development cause idiopathic autism

An international research group led by Professor Toru Takumi (Senior Visiting Scientist, RIKEN Center for Biosystems Dynamics Research) and Researcher Chia-wen Lin at Kobe University Graduate School of Medicine has shown that idiopathic autism is caused by epigenetic abnormalities in hematopoietic cells during fetal development, which results in immune dysregulation in the brain and gut.

2 May 2022

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

Cutaneous T cell lymphomas (CTCLs) are a group of non-Hodgkin lymphomas that develop from T cells and mainly impact the skin with painful lesions.

21 Dec 2020

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Today, the U.S. Food and Drug Administration announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over the next four years.

8 Oct 2020

Study: Pleotropic drugs can have both favorable and unfavorable effects on cell growth, survival

The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.

17 Sep 2020

Study: Understanding second-degree burns is key to treating these complications

New research shows how second-degree burns cause hard-to-treat chronic pain, and this understanding may be key to treating these complications, common in war veterans.

10 Jan 2020

Targeting HDAC2 reduces MDM2 expression and has anti-tumor effects in dedifferentiated liposarcoma

The cover for issue 55 of Oncotarget features Figure 3, "Romidepsin exhibits anti-tumor effect in xenograft model of DDLPS," by Seligson, et al.

4 Oct 2019

New active pharmaceutical ingredient may help against severe forms of testicular cancer

A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.

30 Dec 2016

HDAC inhibitors could improve activity of immunotherapeutic antibodies in lung cancer patients

Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and melanoma; however, only 20 percent of lung cancer patients show a response to these agents.

2 Apr 2016

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Nov 2015

Pilot study shows that anti-cancer drug can activate hidden HIV

A pilot study by HIV researchers from Aarhus University and Aarhus University Hospital in Denmark has shown that an anti-cancer drug can activate hidden HIV.

23 Jul 2014

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine.

18 Jul 2014

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.

3 Jul 2014

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

11 Dec 2013

Researchers discover new approach to treat two lethal metastatic cancers

A potentially powerful new approach to treating two lethal metastatic cancers - triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer - has been discovered by researchers at Mayo Clinic in Florida.

1 Aug 2012

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011